Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Joint Damage in Psoriasis and Psoriatic Arthritis
NCT02483234Phase 2Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- May 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in psoriasis, psoriatic arthritis (PsA), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started May 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02483234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483234.